According to a new report published by Allied Market Research, titled, ” Migraine Drugs by Type, Route of Administration, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.
𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
The report provides an extensive competitive analysis and profiles of the key market players such as Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc. The other players in the value chain (not included in the report) include Novartis International AG, Teva Pharmaceutical Industries Limited, and Sanofi SA.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/2811
𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
- North America occupied two-fifths share of the global migraine drugs market.
- Oral is anticipated to grow with the highest CAGR throughout the forecast period.
- Europe is anticipated to occupy more than one-fourth market share of the global migraine drugs market by 2025.
- Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea, and even disturbed vision in some cases.
Increase in prevalence of migraine, rapid rise in female population, and surge in awareness among patients for migraine treatment & prevention drive the growth of the global migraine drugs market. However, side effects of migraine drugs are expected to limit the market growth. Conversely, emerging new therapies/drugs for migraine treatment and growth opportunities in the emerging nations are expected to present opportunities for the market growth during the forecast period.
By type, abortive medicines accounted for more than three-fourths share of the global migraine drugs market in 2017. Furthermore, by route of administration, the oral segment is anticipated to grow at the highest rate of 3.4% during the forecast period.
𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/2811
North America was the leading revenue contributor to the global market in 2017, owing to surge in demand for better healthcare along with effective government reforms for awareness towards migraine & its prevention. However, Asia-Pacific is expected to grow at the highest CAGR of 4.4% from 2018 to 2025, due to improvements in healthcare infrastructure and rise in demand for better healthcare facilities.
𝗚𝗲𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/migraine-drugs-market
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060